论文部分内容阅读
为探明乳腺癌患者由ＭｃＡｂＧＢ２识别的乳腺癌血清抗原（以下简称血清ＭｃＡｂＧＢ２抗原）水平，应用ＥＬＩＳＡ方法，用抗人乳腺癌血清抗原ＭｃＡｂＧＢ２观察了５０例正常人和６０例乳腺癌患者血清ＭｃＡｂＧＢ２抗原水平。结果：１７例乳腺癌患者术前的血清ＭｃＡｂＧＢ２抗原水平与正常人之间有显著性差异（Ｐ＜０．００１），其阳性符合率达８８．２％（１５／１７）。其中８例乳腺癌患者的血清ＭｃＡｂＧＢ２抗原水平由术前的５７．５±５１．３ｕ／ｍｌ降至术后的２０．６±４．９８ｕ／ｍｌ。４３例在化疗中的乳腺癌术后患者的血清ＭｃＡｂＧＢ２抗原多处于正常水平。由此提示血清ＭｃＡｂＧＢ２抗原可作为乳腺癌标志物，用于乳腺癌的血清学诊断、治疗及预后监测等
To determine breast cancer serum antigen recognized by McAbGB2 in breast cancer patients (hereinafter referred to as serum McAbGB2 antigen), anti-human breast cancer serum McAbGB2 was used to detect serum McAbGB2 antigens in 50 normal and 60 breast cancer patients. Level. Results: Serum McAbGB2 antigen levels in 17 patients with breast cancer were significantly different from those in healthy subjects (P<0.001), and the positive coincidence rate was 88.2% (15/17). The serum McAbGB2 antigen level in 8 breast cancer patients decreased from 57.5±51.3u/ml before surgery to 20.6±4.98u/ml after surgery. The serum McAbGB2 antigen in 43 patients who had breast cancer after chemotherapy was at normal levels. This suggests that serum McAbGB2 antigen can be used as a breast cancer marker for serodiagnosis, treatment and prognosis monitoring of breast cancer